Jane A. McKeating

Jane A. McKeating's AcademicInfluence.com Rankings

Jane A. McKeating

Biology

#6580

World Rank

#9330

Historical Rank

Virology

#196

World Rank

#202

Historical Rank

biology Degrees

Download Badge

Biology

Jane A. McKeating's Degrees

Bachelors Microbiology University of Manchester
PhD Virology University of Oxford

Why Is Jane A. McKeating Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Jane A. McKeating is a professor of molecular biology at Oxford University, and honorary professor at the University of Birmingham, England, where she worked as a professor of molecular virology until 2017. She is listed as a notable scientist in Thomson Reuters' Highly Cited Researchers 2014, ranking her among the top 1% most cited scientists.

(See a Problem?)

Jane A. McKeating's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Complete Replication of Hepatitis C Virus in Cell Culture (2005) (2366)
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry (2007) (1282)
Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication (2002) (1215)
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. (1999) (1093)
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles (2003) (877)
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy (2011) (661)
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. (1990) (612)
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge (2008) (594)
Characterization of Hepatitis C Virus E2 Glycoprotein Interaction with a Putative Cellular Receptor, CD81 (1999) (524)
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. (2006) (484)
Neutralizing antibody response during acute and chronic hepatitis C virus infection. (2004) (462)
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. (2007) (430)
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR (2003) (426)
Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry (2006) (417)
CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection (2004) (407)
Hepatitis C virus cell‐cell transmission in hepatoma cells in the presence of neutralizing antibodies (2007) (392)
Efficient Replication of Hepatitis C Virus Genotype 1a RNAs in Cell Culture (2003) (378)
MAIT cells are activated during human viral infections (2016) (366)
Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates (1992) (297)
Initiation of Hepatitis C Virus Infection Is Dependent on Cholesterol and Cooperativity between CD81 and Scavenger Receptor B Type I (2006) (291)
Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission (2010) (262)
Persistent Hepatitis C Virus Infection In Vitro: Coevolution of Virus andHost (2006) (261)
Viral hepatitis and liver cancer (2017) (254)
Identification of Amino Acid Residues in CD81 Critical for Interaction with Hepatitis C Virus Envelope Glycoprotein E2 (2000) (245)
Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody (1991) (238)
Claudin Association with CD81 Defines Hepatitis C Virus Entry (2010) (236)
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization (1991) (234)
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? (1991) (231)
The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein (2007) (223)
An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies (1989) (223)
Characterization of HIV‐1 neutralization escape mutants (1989) (218)
Multiple effects of silymarin on the hepatitis C virus lifecycle (2010) (218)
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. (2012) (213)
CD81 and Claudin 1 Coreceptor Association: Role in Hepatitis C Virus Entry (2008) (213)
Subcellular Localization of Hepatitis C Virus Structural Proteins in a Cell Culture System That Efficiently Replicates the Virus (2006) (209)
Humoral immune response in acute hepatitis C virus infection. (2005) (208)
Binding of the Hepatitis C Virus E2 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2 (2003) (207)
Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. (2001) (207)
Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner (2004) (203)
Functional Analysis of Cell Surface-Expressed Hepatitis C Virus E2 Glycoprotein (1999) (203)
Inhibition of hepatitis C virus infection by anti‐claudin‐1 antibodies is mediated by neutralization of E2–CD81–Claudin‐1 associations (2010) (195)
Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4 (1991) (188)
Diverse CD81 Proteins Support Hepatitis C Virus Infection (2006) (182)
Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity (2007) (177)
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. (2007) (177)
Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies (2008) (175)
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. (2010) (173)
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. (2013) (161)
Oxidized low‐density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells (2006) (153)
Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 (1993) (149)
Serum-Derived Hepatitis C Virus Infection of Primary Human Hepatocytes Is Tetraspanin CD81 Dependent (2007) (148)
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry†, ‡ (2012) (148)
Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. (1999) (145)
Superinfection Exclusion in Cells Infected with Hepatitis C Virus (2007) (144)
Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. (2014) (143)
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. (2011) (142)
Hepatitis C Virus Induces CD81 and Claudin-1 Endocytosis (2012) (141)
Beta 2 microglobulin enhances the infectivity of cytomegalovirus and when bound to the virus enables class I HLA molecules to be used as a virus receptor. (1987) (137)
Tumour necrosis factors (alpha, beta) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication. (1990) (136)
Polarization Restricts Hepatitis C Virus Entry into HepG2 Hepatoma Cells (2009) (136)
HIV susceptibility conferred to human fibroblasts by cytomegalovirus-induced Fc receptor (1990) (134)
Effect of Cell Polarization on Hepatitis C Virus Entry (2007) (125)
Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. (2018) (124)
Functional Characterization of Intracellular and Secreted Forms of a Truncated Hepatitis C Virus E2 Glycoprotein (2000) (123)
Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation. (2014) (120)
Hepatitis C virus receptor expression in normal and diseased liver tissue (2007) (117)
The past, present and future of neutralizing antibodies for hepatitis C virus (2014) (115)
Binding of Hepatitis C Virus E2 Glycoprotein to CD81 Does Not Correlate with Species Permissiveness to Infection (2000) (112)
Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. (2006) (112)
Characterization of Infectious Retroviral Pseudotype Particles Bearing Hepatitis C Virus Glycoproteins (2004) (109)
Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity (2009) (104)
Hepatitis C virus and the brain (2012) (102)
Genome-to-genome analysis highlights the impact of the human innate and adaptive immune systems on the hepatitis C virus (2017) (102)
The role of the hepatitis C virus glycoproteins in infection (2000) (99)
Protein Kinase A-Dependent Step(s) in Hepatitis C Virus Entry and Infectivity (2008) (97)
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. (1990) (94)
Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. (2009) (93)
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. (2000) (91)
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. (2010) (90)
Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment (2021) (90)
Development of novel therapies for hepatitis C. (2010) (90)
Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gpl20 (1992) (90)
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. (2007) (88)
Hepatitis C virus entry: beyond receptors (2012) (88)
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant (2008) (86)
Cytomegalovirus in urine specimens has host beta 2 microglobulin bound to the viral envelope: a mechanism of evading the host immune response? (1987) (85)
Cytomegalovirus strain AD169 binds beta 2 microglobulin in vitro after release from cells. (1987) (83)
Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain (1995) (81)
Clearance of persistent hepatitis C virus infection using a claudin-1-targeting monoclonal antibody (2015) (79)
A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration (2012) (79)
Insights From Deep Sequencing of the HBV Genome—Unique, Tiny, and Misunderstood (2018) (78)
Structural Flexibility of a Conserved Antigenic Region in Hepatitis C Virus Glycoprotein E2 Recognized by Broadly Neutralizing Antibodies (2014) (77)
Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. (2007) (71)
An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. (1989) (71)
Interferon lambda 4 impacts the genetic diversity of hepatitis C virus (2019) (71)
Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. (2008) (69)
An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission (2013) (69)
Pharmacological characterization of the chemokine receptor, CCR5 (2002) (66)
Enhancement of class I HLA antigen expression by cytomegalovirus: Role in amplification of virus infection (1988) (66)
Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. (2011) (65)
Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein (1995) (65)
Multidrug treatment with nelfinavir and cepharanthine against COVID-19 (2020) (64)
Hepatitis C virus infection of neuroepithelioma cell lines. (2010) (64)
Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses (2014) (62)
Structure and function of the HIV envelope (1989) (62)
Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. (2007) (61)
Naturally Occurring Antibodies That Recognize Linear Epitopes in the Amino Terminus of the Hepatitis C Virus E2 Protein Confer Noninterfering, Additive Neutralization (2011) (61)
Identification of Amino Acid Residues in CD 81 Critical for Interaction with Hepatitis C Virus Envelope Glycoprotein E 2 (1999) (60)
An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease (2021) (58)
Mechanisms of viral entry: sneaking in the front door (2010) (58)
Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. (1991) (56)
Infection of brain cells by diverse human immunodeficiency virus isolates: role of CD4 as receptor. (1989) (53)
Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. (1992) (52)
Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120 (1993) (52)
The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication (2019) (52)
Hepatitis C virus entry and neutralization. (2008) (51)
An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. (1993) (51)
Activated Macrophages Promote Hepatitis C Virus Entry in a Tumor Necrosis Factor-Dependent Manner (2014) (50)
The C-terminal region of the hepatitis C virus E1 glycoprotein confers localization within the endoplasmic reticulum. (1999) (50)
Hepatoma Cell Density Promotes Claudin-1 and Scavenger Receptor BI Expression and Hepatitis C Virus Internalization (2009) (50)
Hepatitis C virus entry and the tetraspanin CD81. (2011) (49)
Evaluation of human and simian immunodeficiency virus plaque and neutralization assays. (1989) (49)
Functional characterization of the V1V2 region of human immunodeficiency virus type 1. (1996) (48)
Entry of hepatitis B and C viruses - recent progress and future impact. (2014) (47)
Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells (2020) (47)
Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication. (2017) (46)
Hepatoma polarization limits CD81 and hepatitis C virus dynamics (2012) (46)
Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. (1992) (44)
The role of the humoral immune response in HIV infection (1996) (43)
Interplay between circadian clock and viral infection (2017) (43)
Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. (1997) (43)
The Circadian Clock and Viral Infections (2020) (42)
Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors. (1993) (41)
Glucocorticoids promote Von Hippel Lindau degradation and Hif-1α stabilization (2017) (41)
Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site (1997) (40)
Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. (1993) (40)
Accurate targeted long-read DNA methylation and hydroxymethylation sequencing with TAPS (2020) (39)
Identification of a monoclonal antibody to abscission tissue that recognises xylose/fucose-containing N-linked oligosaccharides from higher plants (1988) (38)
Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint (2021) (37)
Structural characterization of recombinant human CD81 produced in Pichia pastoris (2008) (37)
Development of a Neutralizing Antibody Response during Acute Primary Human Immunodeficiency Virus Type 1 Infection and the Emergence of Antigenic Variants (1998) (37)
IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria (2014) (36)
Bioportide: an emergent concept of bioactive cell-penetrating peptides (2012) (36)
Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity (1991) (36)
Detection of cytomegalovirus by ELISA in urine samples is inhibited by β2 microglobulin (1986) (36)
Detection of cytomegalovirus in urine samples by enzyme‐linked immunosorbent assay (1985) (36)
Hepatitis C Virus Envelope Glycoprotein Fitness Defines Virus Population Composition following Transmission to a New Host (2012) (35)
Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes (2016) (34)
Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals. (1997) (34)
Hepatitis C virus entry: possible targets for therapy (2008) (34)
In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface (2012) (34)
Detection of cytomegalovirus by DNA-DNA hybridization employing probes labelled with 32-phosphorus or biotin. (1985) (33)
Primary hepatocytes as targets for Hepatitis C virus replication (2008) (32)
Human immunodeficiency viruses: neutralization and receptors. (1988) (32)
N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection (2017) (32)
Monoclonal anti‐envelope antibody AP33 protects humanized mice against a patient‐derived hepatitis C virus challenge (2016) (32)
The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis (2017) (32)
Hepatitis C virus glycoprotein E2 binding to CD81: the role of E1E2 cleavage and protein glycosylation in bioactivity. (2000) (30)
Functional Analysis of Claudin-6 and Claudin-9 as Entry Factors for Hepatitis C Virus Infection of Human Hepatocytes by Using Monoclonal Antibodies (2013) (30)
Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. (2002) (29)
High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease (2017) (28)
Cholesterol-modifying drugs in COVID-19 (2020) (28)
Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein. (1992) (28)
Paracrine Signals From Liver Sinusoidal Endothelium Regulate Hepatitis C Virus Replication (2013) (28)
Regulated expression vectors demonstrate cell-type-specific sensitivity to human immunodeficiency virus type 1 Nef-induced cytostasis. (1997) (28)
Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV‐1 gp120 (1997) (27)
Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. (2013) (26)
HIV-1 neutralization directed to epitopes other than linear V3 determinants. (1991) (26)
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells (2021) (26)
Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant (2015) (26)
Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication (2020) (25)
Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers (2021) (25)
Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera. (1996) (25)
Deep sequencing of hepatitis C virus reveals genetic compartmentalization in cerebrospinal fluid from cognitively impaired patients (2016) (25)
Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation (2016) (25)
Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization. (1993) (23)
Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. (1996) (23)
Clocks, Viruses, and Immunity: Lessons for the COVID-19 Pandemic (2021) (22)
Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. (1992) (21)
Immunogenicity of full length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein. (1996) (21)
A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis (2019) (19)
Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences (2022) (19)
Circadian control of hepatitis B virus replication (2021) (19)
Antigenic variation in HIV. (1990) (18)
Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter (2021) (17)
Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion (2011) (17)
TNF superfamily members promote hepatitis C virus entry via an NF-κB and myosin light chain kinase dependent pathway (2017) (16)
Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors. (2016) (16)
Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure (2019) (16)
Bacterial flagellin promotes viral entry via an NF-kB and Toll Like Receptor 5 dependent pathway (2019) (16)
Hypoxic microenvironment shapes HIV-1 replication and latency (2020) (15)
Metallo supramolecular cylinders inhibit HIV-1 TAR-TAT complex formation and viral replication in cellulo (2018) (15)
The CCCTC-binding factor CTCF represses hepatitis B virus enhancer I and regulates viral transcription (2020) (14)
Association between a defective CCR-5 gene and progression to disease in HIV infection. (1998) (14)
A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81 (2017) (14)
CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro. (1992) (12)
Differential effects of dehydroepiandrosterone and deoxyribonucleosides on DNA synthesis and de novo cholesterogenesis in hepatocarcinogenesis in rats. (1991) (12)
Synchronised infection identifies early rate-limiting steps in the hepatitis B virus life cycle (2020) (12)
Production, Purification and Characterization of Recombinant, Full-Length Human Claudin-1 (2013) (12)
The History of HIV-1 Biological Phenotypes Past , Present and Future (1998) (12)
In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube. (2007) (12)
Diverse CD 81 Proteins Support Hepatitis C Virus Infection (2006) (12)
Hypoxia‐Inducible Factor 1 Alpha–Mediated RelB/APOBEC3B Down‐regulation Allows Hepatitis B Virus Persistence (2021) (12)
CYTOMEGALOVIRUS AND β2 MICROGLOBULIN IN URINE SPECIMENS: RECIPROCAL INTERFERENCE IN THEIR DETECTION IS RESPONSIBLE FOR ARTIFACTUALLY HIGH LEVELS OF URINARY β2 MICROGLOBULIN IN INFECTED TRANSPLANT RECIPIENTS (1988) (11)
Neutralization of human immunodeficiency virus (1992) (11)
Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission☆ (2013) (11)
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus (2019) (11)
Construction and characterization of chimeric hepatitis C virus E 2 glycoproteins : analysis of regions critical for glycoprotein aggregation and CD 81 binding (11)
An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease (2021) (11)
Estimating hepatitis B virus cccDNA persistence in chronic infection† (2020) (11)
A bile acid transporter as a candidate receptor for hepatitis B and D virus entry. (2013) (10)
Identification of Amino Acid Residues Critical for Aggregation of Human CC Chemokines Macrophage Inflammatory Protein (MIP)-1α, MIP-1β, and RANTES (1999) (10)
A Role for CD81 and Hepatitis C Virus in Hepatoma Mobility (2014) (10)
Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models (2020) (10)
The construction and characterization of poliovirus antigen chimeras presenting defined regions of the human T lymphocyte marker CD4. (1994) (9)
Rituximab Treatment in Hepatitis C Infection: An In Vitro Model to Study the Impact of B Cell Depletion on Virus Infectivity (2011) (9)
Oxygen Sensing and Viral Replication: Implications for Tropism and Pathogenesis (2020) (9)
Biological consequences of human immunodeficiency virus type 1 envelope polymorphism: does variation matter? 1995 Fleming Lecture. (1996) (9)
The complexities of hepatitis C virus entry. (2009) (8)
Neutralization of virus. (1992) (8)
Hepatitis C virus infection of cholangiocarcinoma cell lines (2015) (8)
Herpesvirus Saimiri-Transformed Human CD4+ T-Cell Lines: an Efficient Target Cell System for the Analysis of Human Immunodeficiency Virus-Specific Cytotoxic CD8+T-Lymphocyte Activity (1998) (8)
Antigenic Variation within the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120: Effects on Chemokine Receptor Utilization (2001) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
Structural characterization of CD81-Claudin-1 hepatitis C virus receptor complexes. (2011) (8)
A PCR assay to quantify patterns of HBV transcription (2019) (8)
Inoculation of New World Primates With the Human Immunodeficiency Virus (1989) (8)
P0676 : Clearance of persistent hepatitis c virus infection using a monoclonal antibody specific for tight junction protein claudin-1 (2015) (7)
Daytime variation in hepatitis C virus replication kinetics following liver transplant. (2018) (7)
The role of circadian clock pathways in viral replication (2022) (7)
The role of the viral glycoprotein in HIV-1 persistence. (1999) (6)
Type I interferon rapidly restricts infectious hepatitis C virus particle genesis (2014) (6)
BASIC-LIVER, PANCREAS, AND BILIARY TRACT Discordant Role of CD4 T-Cell Response Relative to Neutralizing Antibody and CD8 T-Cell Responses in Acute Hepatitis C (2007) (6)
Supramolecular Cylinders Target Bulge Structures in the 5′ UTR of the RNA Genome of SARS‐CoV‐2 and Inhibit Viral Replication (2021) (6)
Glucose and glutamine availability regulate HepG2 transcriptional responses to low oxygen (2018) (6)
Over the fence or through the gate: how viruses infect polarized cells. (2012) (5)
Mutant CD4 molecules with improved binding to HIV envelope protein gp120 selected by phage display. (1997) (5)
Correction to ‘Viral hepatitis and liver cancer’ (2017) (5)
Synchronized infection identifies early rate-limiting steps in the hepatitis B virus life cycle (2020) (4)
Absolute quantitation of individual SARS-CoV-2 RNA molecules: a new paradigm for infection dynamics and variant differences (2021) (4)
The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication (2019) (4)
The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. (1998) (4)
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure (2020) (4)
O.174 Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus (2006) (4)
Estimation of hepatitis B virus cccDNA persistence in chronic infection using within-host evolutionary rates (2020) (4)
A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort (2016) (3)
Daytime variation in hepatitis C virus replication kinetics following liver transplant (2018) (3)
Hand Stitch, Perspectives (2012) (3)
, between Hypervariable Regions 1 and 2 Is Modulated by a Complex Interplay Glycoprotein to CD 81 Is Strain Specific and Binding of the Hepatitis C Virus E 2 (2002) (3)
Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents (2022) (3)
Heterogeneous Claudin-1 Expression in Human Liver (2013) (3)
HIV infectivity. (1991) (2)
Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model (2022) (2)
Memory cytotoxic SARS-CoV-2 spike protein-specific CD4+ T cells associate with viral control (2022) (2)
Identification of claudin-1 as an essential cellular cell entry factor for hepatitis C virus (2006) (2)
Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection (2015) (2)
O.015 A phase 1 trial of a novel E1E2/MF59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults (DMID 01-002) (2006) (2)
Circadian regulation of SARS-CoV-2 infection in lung epithelial cells (2021) (2)
Time of day of vaccination affects SARS-CoV-2 antibody responses in an observational study of healthcare workers (2021) (2)
The Involvement of Tight Junction Protein Claudin-1 in Hepatitis C Virus Entry (2010) (2)
CONFORMATIONAL GP120 NEUTRALIZATION EPITOPES ON HIV-1 (1991) (2)
Effect of scavenger receptor B-I antagonist, ITX5061, on early hepatitis C virus kinetics in liver transplantation: results of a phase 1b clinical trial (2014) (2)
HEPATITIS Oxidized Low-Density Lipoprotein Inhibits Hepatitis C Virus Cell Entry in Human Hepatoma Cells (2006) (2)
Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease (2022) (1)
Scavenger receptor B-I antagonist ITX5061 modulates early HCV kinetics in patients undergoing liver transplantation: results of a phase Ib clinical trial (2013) (1)
Machine Stitch: Perspectives (2011) (1)
Persistent Hepatitis C Virus Infection In Vitro: Coevolution of Virus and Host (cid:1) † (2006) (1)
Accurate targeted long-read DNA methylation and hydroxymethylation sequencing with TAPS (2020) (1)
Hypoxic gene expression in chronic hepatitis B infected patients is not observed in state-of-art in vitro and mouse infection models (2020) (1)
58 HRas SIGNAL TRANSDUCTION MEDIATES HEPATITIS C VIRUS CELL ENTRY BY TRIGGERING THE ASSEMBLY OF THE HOST TETRASPANIN RECEPTOR COMPLEX (2013) (1)
An ACAT inhibitor regulates SARS-CoV-2 replication and antiviral T cell activity (2022) (1)
The Role of β2-Microglobulin and Class I HLA Heavy Chain in Cytomegalovirus Infection (1988) (1)
Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus (2018) (1)
Are the Patterns of Cytomegalovirus Viral Load Seen After Solid Organ Transplantation Affected by Circadian Rhythm? (2022) (1)
CD4 antagonists : Novel approaches in HIV chemotherapy (1992) (1)
A Role for B Cells to Transmit Hepatitis C Virus Infection (2020) (1)
HIV infactivity (1991) (1)
402 Human hepatic sinusoidal endothelial cells (HSEC) interact with hepatitis C virus (HCV) E2 glycoprotein via DCSign and Lsign (2004) (1)
OP23 Vascular endothelial growth factor activation of liver sinusoidal endothelial cells via vascular endothelial growth factor receptor-2 regulates hepatocellular hepatitis C virus replication (2010) (1)
Identification of Anti-COVID-19 Agents, Cepharanthine and Nelfinavir, and Their Potential Usage for Combination Treatment (2020) (1)
Circadian regulation of human immunodeficiency virus type 1 replication (2022) (0)
Detection of gp120 hiv 1 and antibodies to defined regions of gp120 in human serum correlation with hiv 1 neutralization (1989) (0)
REVIEW Hepatitis C virus entry: beyond receptors (2011) (0)
Lentiviral hepatitis B pseudotype entry requires NTCP and additional hepatocyte-specific factors (2016) (0)
University of Birmingham Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection (2015) (0)
827 EXPERIMENTAL HCV VACCINE COMBINING ADENOVIRUS AND PROTEIN ELICITS POTENT T-CELL RESPONSES AND NEUTRALIZING ANTIBODIES IN RODENTS (2012) (0)
Author response: Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences (2021) (0)
therapy Hepatitis C virus entry: possible targets for (2010) (0)
University of Birmingham Superinfection Exclusion in Cells Infected with Hepatitis C Virus (2007) (0)
Desombere, I. et al. (2016) Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus (2015) (0)
Hepatitis C virus kinetics after liver transplantation to study the role of a small molecule inhibitor of viral entry (2013) (0)
Oxygen-Dependent Histone Lysine Demethylase 4 Restricts Hepatitis B Virus Replication (2022) (0)
Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus (2020) (0)
IDENTIFICATION OF EGFR SIGNALLING PATHWAYS MEDIATING HEPATITIS C VIRUS ENTRY (2011) (0)
P206 Hepatitis C Virus Compartmentalisation: Unravelling Genetic Complexity Within The Liver (2014) (0)
Hepatitis C virus infection of cholangiocarcinoma cell lines Short Title: HCV infects cholagiocarcinoma cells Article Type: Standard (2015) (0)
The HCV Envelope Glycoprotein Down-Modulates NF-κB Signalling and Associates With Stimulation of the Host Endoplasmic Reticulum Stress Pathway (2022) (0)
Elimination of the immunodominant B cell epitopes on the V3 loop of HIV gp120 (1998) (0)
Identiﬁcation of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies (cid:1) (2008) (0)
7 T CELLS FACILITATE HEPATITIS C VIRUS TRANSMISSION TO POLARISED LIVER AND BRAIN CELL LINES, REVEALING A NEW ROLE FOR VIRAL QUASISPECIES (2013) (0)
SOLUBLE CD4 BINDING TO HIV-1 VIRIONS CAUSES GP120 TO DISSOCIATE FROM GP41 (1991) (0)
gpl20 Important in CD4 Binding and Human Immunodeficiency Virus Type (0)
Estimating hepatitis B virus cccDNA persistence in chronic infection (2020) (0)
5[beta]-reductase (AKR1D1) is a regulator of glucose homeostasis in human hepatocytes and development of model systems to define its role in metabolic liver disease (2016) (0)
SUBSTITUTION OF PBMC-DERIVED GP120 CODING SEQUENCES INTO AN INFECTIOUS MOLECULAR CLONE OF HIV-1 (1993) (0)
CD4 antagonists. (1992) (0)
Author Correction: Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models (2020) (0)
Oxygenation and miR138-5 p act as rheostats in APOBEC3B-mediated Hepatitis B Virus control (2020) (0)
P97 Lymphocyte-hepatocyte interactions: hepatitis C virus changes the rules (2011) (0)
A non-Hodgkin's lymphoma immunoglobulin binds to the envelope 2 (E2) glycoprotein of hepatitis C virus (2001) (0)
Full Title: Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection Short Title: Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection (2015) (0)
Glucocorticoids promote Von Hippel Lindau (pVHL) degradation and Hif-1α stabilization (2017) (0)
VIRAL HEPATITIS Paracrine Signals From Liver Sinusoidal Endothelium Regulate Hepatitis C Virus Replication (2014) (0)
Hypoxia dampens innate immune signalling at early time points and increases Zika virus replication in iPSC-derived macrophages (2023) (0)
1566. Is Primary CMV Infection Post-transplant Influenced by Circadian Rhythms? (2018) (0)
Using Monoclonal Antibodies Virus Infection of Human Hepatocytes by Claudin-9 as Entry Factors for Hepatitis C Functional Analysis of Claudin-6 and (2014) (0)
The Role of CD4 Antigen in HIV Infection (1989) (0)
University of Birmingham Primary hepatocytes as targets for hepatitis C virus replication. (2009) (0)
Sleep and circadian rhythm disruption alters the lung transcriptome to predispose to viral infection (2022) (0)
Hypoxic microenvironment shapes HIV-1 replication and latency (2020) (0)
The construction and characterization of poliovirus antigen chimeras presenting defined regions of the human T lymphocyte marker CD 4 (2007) (0)
P188 A HIGH-THROUGHPUT HDV INFECTION MODEL SYSTEM FOR SCREENING OF ANTIVIRALS AND HOST-TARGETING COMPOUNDS (2014) (0)
P147 CD4+ T CELL EGRESS THROUGH HEPATIC EPITHELIA HAS PROFOUND IMPLICATIONS FOR PHENOTYPE AND FUNCTION (2014) (0)
Editorial overview - virus entry: towards reality - refining models of virus entry. (2014) (0)
Model systems to define the role of AKR1D1 in metabolic liver disease (2015) (0)
Metallo supramolecular cylinders inhibit HIV-1 TAR-TAT complex formation and viral replication in cellulo (2018) (0)
P622 MODELLING HCV REPLICATION IN AN INFLAMED LIVER ENVIRONMENT: A NEW ROLE FOR STROMAL EXPRESSED VAP-1 TO REGULATE VIRAL REPLICATION (2014) (0)
An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity. (2023) (0)
1374 LYMPHOCYTE-HEPATOCYTE INTERACTIONS: HEPATITIS C VIRUS CHANGES THE RULES (2011) (0)
P140 MODELLING THE LIVER IMMUNE MICROENVIRONMENT: FACTORS THAT DEFINE ANTIVIRAL ACTIVITY OF T CELLS (2014) (0)
New Host Composition following Transmission to a Fitness Defines Virus Population Hepatitis C Virus Envelope Glycoprotein (2012) (0)
CHARACTERIZATION OF A HUMAN SERUM SELECTED HIV-1 ESCAPE MUTANT RESISTANT TO NEUTRALIZATION BY MONOCLONAL-ANTIBODIES MAPPING TO THE CD4 BINDING-SITE OF GP120 (1993) (0)
Hypoxia is more than HIFs. (2022) (0)
Time-of-Day Variation in SARS-CoV-2 RNA Levels during the Second Wave of COVID-19 (2022) (0)
Surface Sensibilities: Utilising machine stitch to render surface and mark-making (2010) (0)
Bacterial flagellin promotes viral entry via an NF-kB and Toll Like Receptor 5 dependent pathway (2019) (0)
Monoclonal antibodies that target the hepatitis C virus envelope proteins prevent in vivo infection of an escape variant isolated from a liver transplant patient (2012) (0)
P191 HEPATITIS B AND C VIRUS PROMOTE CROSSTALK BETWEEN HYPOXIA AND GLUCOCORTICOID SIGNALLING PATHWAYS TO RE-PROGRAMME HEPATOCYTE METABOLISM AND TO EVADE HOST INTERFERONS (2014) (0)
HIV-1 epitope expression on a chimaeric poliovirus vaccine vector (1989) (0)
TARGETING HEPATOCYTE RECEPTOR TYROSINE KINASES BY ERLOTINIB AND INHIBITION OF HEPATITIS C VIRUS INFECTION IN VIVO (2010) (0)
Response : Receptor-Mediated Activation of Immunodeficiency Viruses in Viral Fusion (1991) (0)
An Emerging Image (2010) (0)
Lymphocyte interactions with hepatocytes: distinct mechanisms for T and B cells (2011) (0)
Author response: Interferon lambda 4 impacts the genetic diversity of hepatitis C virus (2019) (0)
University of Birmingham High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease (2016) (0)
of Birmingham Persistent hepatitis C virus infection in vitro: Coevolution of virus and host (2006) (0)
Unravelling the circadian transcriptome and epigenome of the human liver (2022) (0)
University of Birmingham Neutralizing antibody response during acute and chronic hepatits C virus infection (2004) (0)
Enhancement of BRET 2 Assay Robustness and Handling Utilizing the PerkinElmer EnVision Plate (2015) (0)
The Complexities of Hepatitis C Virus Entry (2009) (0)
1152 HEPATITIS C VIRUS ENTRY INTO HUMAN HEPATOCYTES IS DEPENDENT ON CLAUDIN-1 BUT NOT ON CLAUDIN-6 AND CLAUDIN-9 (2013) (0)
Investigations into the receptor requirements of Hepatitis C Virus (HCV) pseudoparticles and cell culture grown virions (2006) (0)
University of Birmingham Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies (2015) (0)
THE FIRST AND 2ND VARIABLE REGIONS OF HIV-1 GP120 AFFECT THE ABILITY OF THE ENVELOPE GLYCOPROTEIN TO BIND CD4 (1995) (0)
Comment on : 1 Sodium taurocholate cotransporting polypeptide is a functional receptor for 2 human hepatitis B and D virus (2013) (0)
HIV TARGET-CELL INTERACTIONS (1990) (0)
Pharmacological analysis of CCR5 receptors using S-35 -GTP gamma S binding (2001) (0)
1178 A NANOBODY RECOGNIZING A NOVEL EPITOPE IN HEPATITIS C VIRUS GLYCOPROTEIN E2 BROADLY NEUTRALIZES VIRUS ENTRY AND INHIBITS CELL–CELL TRANSMISSION (2013) (0)
University of Birmingham Diverse CD81 Proteins Support Hepatitis C Virus Infection (2006) (0)
Interplay between circadian clock and viral infection (2017) (0)
P1265 UNDERSTANDING THE IMPACT OF AGE ON HEPATIC INNATE IMMUNE RESPONSES IN HEPATITIS C VIRUS PATHOGENESIS AND RESPONSE TO INTERFERON THERAPY (2014) (0)

This paper list is powered by the following services:

Other Resources About Jane A. McKeating

What Schools Are Affiliated With Jane A. McKeating?

Jane A. McKeating is affiliated with the following schools:

Jane A. McKeating's Academic­Influence.com Rankings